Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Moxifloxacin Increases Heart Rate in Humans.

Mason JW, Moon TE.

Antibiotics (Basel). 2017 Feb 5;6(1). pii: E5. doi: 10.3390/antibiotics6010005.

2.

A fundamental relationship between intraventricular conduction and heart rate.

Mason JW, Badilini F, Vaglio M, Lux RL, Aysin B, Moon TE, Heinz B, Strachan I.

J Electrocardiol. 2016 May-Jun;49(3):362-70. doi: 10.1016/j.jelectrocard.2016.03.008. Epub 2016 Mar 5.

PMID:
27034123
3.

Automated measurements for individualized heart rate correction of the QT interval.

Mason JW, Moon TE.

Clin Trials. 2015 Apr;12(2):149-55. doi: 10.1177/1740774514566332. Epub 2015 Jan 9.

PMID:
25576068
4.
5.

Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management.

Mason JW, Moon TE.

Cancer Manag Res. 2013 Jul 29;5:179-85. doi: 10.2147/CMAR.S34352. Print 2013.

6.

Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.

Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J.

Clin Cancer Res. 2012 May 15;18(10):2913-21. doi: 10.1158/1078-0432.CCR-11-2785. Epub 2012 Mar 27.

7.

Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.

Darpo B, Lee SK, Moon TE, Sills N, Mason JW.

J Clin Pharmacol. 2010 Aug;50(8):895-903. doi: 10.1177/0091270009355449. Epub 2010 May 19.

PMID:
20484618
8.

Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.

Mason JW, Florian JA Jr, Garnett CE, Moon TE, Selness DS, Spaulding RR.

J Clin Pharmacol. 2010 Nov;50(11):1249-59. doi: 10.1177/0091270009356298. Epub 2010 Feb 9.

PMID:
20145260
9.

Electrocardiographic reference ranges derived from 79,743 ambulatory subjects.

Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B.

J Electrocardiol. 2007 Jul;40(3):228-34. Epub 2007 Feb 5.

PMID:
17276451
10.

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

Powell JS, Ragni MV, White GC 2nd, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ, Hurst D.

Blood. 2003 Sep 15;102(6):2038-45. Epub 2003 May 22.

PMID:
12763932
11.

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators.

Lancet. 2002 Jun 15;359(9323):2053-8.

PMID:
12086757
12.

Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996.

Harris RB, Griffith K, Moon TE.

J Am Acad Dermatol. 2001 Oct;45(4):528-36.

PMID:
11568742
13.

Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults.

Foote JA, Harris RB, Giuliano AR, Roe DJ, Moon TE, Cartmel B, Alberts DS.

Int J Cancer. 2001 Jan 20;95(1):7-11.

14.

Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study.

Cartmel B, Moon TE, Levine N, Rodney S, Alberts D.

Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):999-1002.

15.

Effects of long-term intake of retinol on selected clinical and laboratory indexes.

Cartmel B, Moon TE, Levine N.

Am J Clin Nutr. 1999 May;69(5):937-43.

PMID:
10232634
16.

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS.

J Clin Oncol. 1998 Mar;16(3):1103-11.

PMID:
9508197
17.

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.

Cancer Res. 1998 Feb 1;58(3):479-84.

18.

Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.

Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng YM, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61.

19.

Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.

Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng YM, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56.

20.

Retinoids in prevention of skin cancer.

Moon TE, Levine N, Cartmel B, Bangert JL.

Cancer Lett. 1997 Mar 19;114(1-2):203-5.

PMID:
9103292
21.

Attitudes and practices of primary care physicians for prostate cancer screening.

Hoffman RM, Papenfuss MR, Buller DB, Moon TE.

Am J Prev Med. 1996 Jul-Aug;12(4):277-81.

PMID:
8874692
22.

Design and analysis of the ESVEM Trial.

Anderson KP, Hartz VL, Hahn EA, Moon TE.

Prog Cardiovasc Dis. 1996 May-Jun;38(6):489-502.

PMID:
8638029
23.

The Myocarditis Treatment Trial: design, methods and patients enrollment.

Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM, Mason JW.

Eur Heart J. 1995 Dec;16 Suppl O:162-7.

PMID:
8682088
24.

Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. The Southwest Skin Cancer Prevention Study Group.

Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, Peng YM, Ritenbaugh C, Meyskens F, Alberts D.

Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):661-9.

25.

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE.

N Engl J Med. 1995 Aug 3;333(5):269-75.

26.

Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial.

Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS.

J Natl Cancer Inst. 1994 Apr 6;86(7):539-43.

27.
28.

The new cancer prevention and control.

Gritz ER, Moon TE.

Cancer Epidemiol Biomarkers Prev. 1992 Mar-Apr;1(3):163-5. No abstract available.

29.

Study of strategies for the recruitment of elders including the use of community volunteers.

Cartmel B, Moon TE.

J Am Geriatr Soc. 1992 Feb;40(2):173-7.

PMID:
1740603
30.

Study design for the prevention of aerodigestive tract cancers.

Moon TE.

Adv Exp Med Biol. 1992;320:105-9. Review. No abstract available.

PMID:
1442274
31.

Planning the analysis of a breast cancer prevention trial.

Moon TE.

Prev Med. 1991 Jan;20(1):109-18.

PMID:
2008420
32.

Estrogens and disease prevention.

Moon TE.

Arch Intern Med. 1991 Jan;151(1):17-8. No abstract available.

PMID:
1985592
33.

The risk of developing subsequent nonmelanoma skin cancers.

Schreiber MM, Moon TE, Fox SH, Davidson J.

J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1114-8.

PMID:
2273111
34.

Interpretation of cancer prevention trials.

Moon TE.

Prev Med. 1989 Sep;18(5):721-31.

PMID:
2694166
35.

Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease.

Berdeaux DH, Meyskens FL Jr, Parks B, Tong T, Loescher L, Moon TE.

Cancer. 1989 Apr 1;63(7):1430-6.

PMID:
2920369
36.

Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.

Meyskens FL Jr, Berdeaux DH, Parks B, Tong T, Loescher L, Moon TE.

Cancer. 1988 Sep 15;62(6):1207-14. Erratum in: Cancer 1989 Apr 1;63(7):1436.

PMID:
3409189
37.

The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.

Ahmann FR, Jones SE, Moon TE.

J Surg Oncol. 1988 Feb;37(2):116-22.

PMID:
3343839
38.

Development and use of a natural history data base of breast cancer studies.

Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E.

Am J Clin Oncol. 1987 Oct;10(5):396-403.

PMID:
3310604
39.

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.

Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T.

Am J Clin Oncol. 1987 Oct;10(5):387-95.

PMID:
3310603
40.
41.

The role of lymphangiography in vulvar carcinoma.

Weiner SA, Lee JK, Kao MS, Moon TE.

Am J Obstet Gynecol. 1986 May;154(5):1073-5.

PMID:
3706432
42.

Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide.

Brooks RJ, Jones SE, Salmon SE, Chase EM, Davis SL, Moon TE, Giordano GF, Ketchel SJ, Jackson RA.

NCI Monogr. 1986;(1):135-7.

PMID:
3534586
43.

Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC).

Ahmann FR, Jones SE, Moon TE, Hammond N, Miller TP, Durie BG.

Cancer. 1985 Aug 15;56(4):730-7.

PMID:
4016669
44.

Clinical-biologic patterns of metastatic melanoma and their effect on treatment.

Berdeaux DH, Moon TE, Meyskens FL Jr.

Cancer Treat Rep. 1985 Apr;69(4):397-401.

PMID:
3995510
45.
46.

Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma.

Meyskens FL Jr, Loescher L, Moon TE, Takasugi B, Salmon SE.

J Clin Oncol. 1984 Nov;2(11):1223-8.

PMID:
6387058
47.

Using a database of protocol studies to evaluate therapy: a breast cancer example.

Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, Buzdar A, Montague E.

Stat Med. 1984 Oct-Dec;3(4):333-9. No abstract available.

PMID:
6528133
48.

Kinetics of clonogenic melanoma cell proliferation and the limits on growth within a bilayer agar system.

Thomson SP, Moon TE, Meyskens FL Jr.

J Cell Physiol. 1984 Oct;121(1):114-24.

49.

Plasma kinetics of oral retinol in cancer patients.

Goodman GE, Alberts DS, Peng YM, Beaudry J, Leigh SA, Moon TE.

Cancer Treat Rep. 1984 Sep;68(9):1125-33.

PMID:
6478452
50.

Evaluation of an automated image analysis system for counting human tumor colonies.

Salmon SE, Young L, Lebowitz J, Thomson S, Einsphar J, Tong T, Moon TE.

Int J Cell Cloning. 1984 May;2(3):142-60.

PMID:
6736686

Supplemental Content

Support Center